Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Kedudukan dalam Saham #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Harga Saham
$4.74
Disegerakkan terakhir: 2026-08-31
Modal Pasaran
$372.19M
Perubahan (1 hari)
-2.47%
Perubahan (1 tahun)
-1.04%
Negara
US
Perdagangan Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategori

Nisbah P/B bagi Lexeo Therapeutics, Inc. Common Stock (LXEO)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Lexeo Therapeutics, Inc. Common Stock, nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk Lexeo Therapeutics, Inc. Common Stock dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
6.828 -
US
7.5116 -
NL
3.9942 -
AU
8.2199 -
US
- -
CH